Loading...
 
Toggle Health Problems and D

Prostate cancer 3X more likely to be lethal if both low vitamin D and poor Vitamin D Binding gene – March 2020

Circulating 25-hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer

International Journal of Cancer Volume 144 Issue 10 March 2020
Chen Yuan©1,2, Irene M. Shui1, Kathryn M. Wilson1,3, Meir J. Stampfer1,3,4, Lorelei A. Mucci1'4 and Edward L. Giovannuccl1,3,4
1 Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA
2 department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
3 department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA
4 dhanning Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

VitaminDWiki
Vitamin D Binding Protein category listing has 139 items and the following introduction

Vitamin D Binding Protein (GC) gene can decrease the bio-available Vitamin D that can get to cells,

  • GC is not the only such gene - there are 3 others, all invisible to standard Vitamin D tests
  • The bio-available calculation does not notice the effect of GC, CYP27B1, CYP24A1, and VDR
  • The actual D getting to the cells is a function of measured D and all 4 genes
  • There is >2X increase in 8+ health problems if have poor VDBP (GC)
  • It appears that VDBP only blocks oral vitamin D,

Pages listed in both of the categories Prostate Cancer and Vitamin D Binding Protein

Pages listed in both of the categories Prostate Cancer and Vitamin D Receptor


We previously found that higher total 25-hydroxyvitamin D [25(OH)D] levels were associated with lower risk of lethal prostate cancer. However, the relationships of bioavailable 25(OH)D and vitamin D binding protein (VDBP) with risk of advanced and lethal prostate cancer are unclear. In a prospective case-control study of 156 pairs of advanced prostate cancer cases and controls, we directly measured prediagnostic circulating 25(OH)D and VDBP and calculated bioavailable 25(OH)D using a validated formula. We examined the association of bioavailable 25(OH)D and VDBP levels with risk of advanced and lethal prostate cancer and whether total 25(OH)D levels interacted with VDBP levels to affect the risk. Conditional logistic models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Compared to total 25(OH)D (ptrend = 0.02), bioavailable 25(OH)D levels were not more strongly associated with risk of advanced prostate cancer (ptrend = 0.14). Although VDBP levels were not associated with risk of advanced prostate cancer (ptrend = 0.16), we observed an interaction between total 25(OH)D levels and VDBP levels in relation to risk of advanced prostate cancer (Pmteraction = 0.03).
Compared to those with total 25(OH)D levels below the median and VDBP levels above the median (at highest risk), men with both levels above the median had a multivariable-adjusted OR of 0.31 (95% Cl, 0.15-0.65) for advanced prostate cancer. We observed similar results when we restricted the analyses to 116 lethal prostate cancer cases and their controls. Our data suggest that VDBP levels may modify the association between total 25(OH)D levels and risk of advanced and lethal prostate cancer.


Created by admin. Last Modification: Thursday July 11, 2019 12:50:14 GMT-0000 by admin. (Version 3)
See any problem with this page? Report it (FINALLY WORKS)